This annual event gives investors and industry analysts an opportunity to meet with Novartis executives who share deep insights into the company’s growth, pipeline and strategy.
We have delivered strong operational performance over the last three years and are positioned to maintain the momentum. The executives highlighted five assets that are growth drivers in major therapeutic areas, as well as five mid-to-late stage assets in Oncology and six mid-to-late stage assets in Pharmaceuticals with key milestones expected in 2021 and 2022.
We are also taking significant steps to achieve a consistent leadership position in the Environment, Social, Governance (ESG) space as we work to become the leading medicines company powered by data science and advanced therapy platforms.
